Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 19.79% is 117% above its 5-year average of -117.23%, near the high end of its 5-year range (-14950.22%–55.00%).
38.62% above its 12-month average of 14.28%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1.43%.
EBITDA MARGIN
19.79%
EBITDA MARGIN AVG TTM
14.28%
EBITDA MARGIN AVG 3Y
-6.99%
EBITDA MARGIN AVG 5Y
-117.23%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+38.62%
CURRENT VS 3Y AVG
+383.07%
CURRENT VS 5Y AVG
+116.88%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$2.06B
EBITDA Margin
39.14%
TTM Avg
19.43%
3Y Avg
-11.55%
5Y Avg
-189.29%
Market Cap
$2.05B
EBITDA Margin
7.12%
TTM Avg
6.21%
3Y Avg
-1.19%
5Y Avg
-11.55%
Market Cap
$2.11B
EBITDA Margin
10.90%
TTM Avg
10.48%
3Y Avg
9.90%
5Y Avg
9.38%
Market Cap
$2.02B
EBITDA Margin
-3042.18%
TTM Avg
-3200.65%
3Y Avg
-2392.49%
5Y Avg
-2392.49%
Market Cap
$2.02B
EBITDA Margin
40.34%
TTM Avg
23.31%
3Y Avg
-20.04%
5Y Avg
-112.62%
Market Cap
$2.01B
EBITDA Margin
1.74%
TTM Avg
-0.52%
3Y Avg
3.36%
5Y Avg
2.51%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alvotech (ALVO) | $2.07B | 19.79% | 14.28% | -6.99% | -117.23% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.06B | 39.14% | 19.43% | -11.55% | -189.29% |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.05B | 7.12% | 6.21% | -1.19% | -11.55% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 10.90% | 10.48% | 9.90% | 9.38% |
| Immunome, Inc. (IMNM)vs › | $2.02B | -3042.18% | -3200.65% | -2392.49% | -2392.49% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 40.34% | 23.31% | -20.04% | -112.62% |
| Fortrea Holdings Inc. (FTRE)vs › | $2.01B | 1.74% | -0.52% | 3.36% | 2.51% |
| AxoGen, Inc. (AXGN)vs › | $2.00B | 0.15% | 1.29% | -6.34% | -9.86% |
| Azenta, Inc. (AZTA)vs › | $1.97B | 8.41% | 9.50% | 6.21% | 7.73% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.17B | -18934.67% | -10834.15% | -7159.00% | -5150.48% |
Gross Margin
60.5%
EBITDA Margin
19.8%
Operating Margin
9.6%
Net Margin
-36.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1.43% |
| 2026-03-31 | 18.78% |
| 2025-12-31 | 35.24% |
| 2025-09-30 | 3.23% |
| 2025-06-30 | 15.56% |
| 2025-03-31 | 14.19% |
| 2024-12-31 | 14.30% |
| 2024-09-30 | 20.53% |
| 2024-06-30 | 50.02% |
| 2024-03-31 | -111.88% |
| 2023-12-31 | -135.45% |
| 2023-08-31 | -461.27% |
| 2023-06-30 | -1963.64% |
| 2023-03-31 | -576.36% |
| 2022-12-31 | -316.30% |
| 2022-09-30 | -299.26% |
| 2022-06-30 | -317.73% |
| 2022-03-31 | -14950.22% |
| 2021-12-31 | 55.00% |
| 2021-06-30 | -7188.41% |
| 2021-03-31 | -7188.41% |
| 2020-12-31 | -1.41% |
| 2020-09-30 | -386.86% |
| 2020-06-30 | -181.82% |
| 2020-03-31 | -181.82% |
| 2019-12-31 | -146.75% |
| 2019-09-30 | -146.75% |
| 2019-06-30 | -146.75% |
| 2019-03-31 | -146.75% |
